Axovant's Cupboard Is Bare After Lead Dementia Program Fails
'New year, new me' is a mantra to be adopted by Swiss drug developer Axovant as it seeks new products to fill its pipeline. The CNS-focused company is floundering having ended development of its lead compound intepirdine following another clinical trial failure.
You may also be interested in...
Denovo Dusts Down Lundbeck's Failed Alzheimer's Drug
The Danish group put the 5-HT6 antagonist on the shelf after three failed late-stage trials but Denovo believes that idalopirdine could still work for a subset of Alzheimer's patients.
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.